At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 209 enrolled
Drug / intervention
MORAb-004 +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel With MORAb-004 in Metastatic Soft Tissue Sarcoma
In Brief
A Phase 2 clinical trial evaluating MORAb-004, Gemcitabine, and 2 other interventions for Metastatic Soft Tissue Sarcoma. Completed, enrolled 209 participants across 29 sites in 6 countries.
Detailed Summary
This study is being done to see if MORAb-004 increases the effectiveness of the chemotherapies gemcitabine and docetaxel in people with metastatic Soft Tissue Sarcoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Soft Tissue Sarcoma
CountriesAustralia, Belgium, France, Italy, Netherlands, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 2012
Enrollment StartAug 2012
Primary CompletionAug 2015
Study CompletionAug 2016
TodayJul 2026
First PostedApr 10, 2012
Enrollment StartAug 7, 2012
Primary CompletionAug 11, 2015
Study CompletionAug 2, 2016
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 14.2 years ago
Interventions
MORAb-004drug
IV, Days 1 and 8 of every cycle until disease progression
Gemcitabinedrug
IV, Days 1 and 8 of each cycle until disease progression
Docetaxeldrug
IV, Day 8 of every cycle until disease progression
Gemcitabinedrug
IV, Days 1 and 8 of each cycle until disease progression
Docetaxeldrug
IV, Day 8 of every cycle until disease progression
Placebodrug